SCHEMBL17757274

SCHEMBL17757274

CN1CCC(N2/C(=N/Cc3cccc(Cl)c3)C3(CCNCC3)Nc3ccccc32)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACAT2 Q9BWD1 3/20 0.54
▸ HTR6 P50406 4/20 0.34
▸ CHRM2 P08172 2/20 0.34
▸ CHRM3 P20309 2/20 0.34
▸ SLC6A4 P31645 2/20 0.33
▸ OPRM1 P35372 1/20 0.33
▸ SLC6A2 P23975 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ GLA P06280 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HTT P42858 1/20 0.32
▸ ATM Q13315 1/20 0.32
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ HTR2C P28335 1/20 0.32
▸ HTR2B P41595 1/20 0.32
▸ AMPD2 Q01433 1/20 0.32
▸ THRB P10828 1/20 0.32
▸ HDAC1 Q13547 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21982460 0.79 ACAT2 (0.43) ACAT2HTR6SLC6A4GAAHTR2C
SCHEMBL17757269 0.78 ACAT2 (0.56) ACAT2HTR6SLC6A4SLC6A2GAA
SCHEMBL17757263 0.78 ACAT2 (0.43) ACAT2HTR6CHRM2CHRM3KDM4E
SCHEMBL17757268 0.77 ACAT2 (0.46) ACAT2HTR6MAPTL3MBTL1AMPD2
SCHEMBL17757951 0.75 ACAT2 (0.56) ACAT2HTR6SLC6A4SLC6A2GAA
SCHEMBL17757272 0.75 ACAT2 (0.50) ACAT2KDM4EGAAAMPD2
SCHEMBL17757275 0.72 ACAT2 (0.41) ACAT2MAPT
SCHEMBL21982537 0.72 ACAT2 (0.54) ACAT2HTR6CHRM3SLC6A4SLC6A2
SCHEMBL17757952 0.71 ACAT2 (0.56) ACAT2HTR6CHRM3SLC6A4SLC6A2
SCHEMBL17757949 0.71 ACAT2 (0.43) ACAT2HTR6GAAMAPTAMPD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) 2020-05-12 — — US disclosed
WO-2016075137-A1 SPIROPYRAZINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (DE) 2016-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647687-B2 Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death AIFM2, BAD, AIFM1 ACAT2 1935/4885HTR6 1352/4885CHRM2 4801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback